politics
FDA Panel Reviews Moderna's mRNA Flu Vaccine for Older Adults
18 Haziran 2026The Guardian
- Moderna is seeking FDA approval for its new flu vaccine, mFlusiva, aimed at individuals aged 50 and older. This vaccine represents a pioneering use of mRNA technology, previously instrumental in combating the Covid-19 pandemic.
- The FDA advisory committee is currently reviewing the vaccine, which is crucial as the winter flu season approaches.
- The FDA's consideration of mFlusiva comes at a time when the healthcare community is seeking innovative solutions to improve flu vaccination rates and efficacy. The success of mRNA technology in Covid-19 vaccines has set a precedent that could influence future vaccine development across various viral infections.
- The introduction of an mRNA-based flu vaccine could revolutionize how we approach seasonal influenza, potentially offering more effective and rapid responses to flu strains. As the FDA weighs this decision, the implications for public health and vaccine development are significant, particularly in the context of ong…
NewsAI özeti
This article is for informational purposes only and does not constitute medical advice. Readers should consult healthcare professionals for personal health decisions.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.